ZELTIQ could get boost from new product, says Stifel After ZELTIQ introduced CoolSmooth, Stifel reports that the company is working with the FDA to enable the product to be used on thighs. After conducting checks, the firm sees significant demand for a thigh indication and believes that the new product increases the chances that the company's results will beat expectations. Stifel keeps a $28 price target and Buy rating on the shares.
News For ZLTQ From The Last 14 Days
Check below for free stories on ZLTQ the last two weeks.